Failure to Satisfy Listing Rule (Form 8-K)

Item 3.01 Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing.

On February 6, 2026, Lunai Bioworks Inc. (the "Company") received a letter from the Listing Qualifications Staff (the "Staff") of The Nasdaq Stock Market LLC ("Nasdaq") notifying the Company that the Staff had determined to delist the Company's securities from Nasdaq.

As previously disclosed, the Company timely requested a hearing before the Nasdaq Hearings Panel (the "Panel") to appeal the Staff's determination.

On February 17, 2026, the Company received written notice from Nasdaq that the Panel has granted the Company's request for a hearing. The hearing has been scheduled for March 26, 2026. As a result of the hearing request, the delisting action referenced in the Staff's determination letter has been stayed pending a final written decision by the Panel.

There can be no assurance that the Panel will grant the Company's request for continued listing or that the Company will be able to maintain compliance with Nasdaq's continued listing requirements.